{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:07:29Z","timestamp":1784038049114,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangdong Provincial Hospital Pharmacy Research Fund","award":["No. 2025A01031"],"award-info":[{"award-number":["No. 2025A01031"]}]},{"name":"the Healthcare Public Welfare Initiative-Pharmaceutical Research Special Project of China Zhongguancun Precision Medicine Science and Technology Foundation","award":["No. ZGC-YXKY-37"],"award-info":[{"award-number":["No. ZGC-YXKY-37"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02106-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:57:35Z","timestamp":1772024255000},"page":"1315-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn\u2019s disease"],"prefix":"10.1007","volume":"48","author":[{"given":"Jialin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"2","key":"2106_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/tcrm.2007.3.2.301","volume":"3","author":"G Poggioli","year":"2007","unstructured":"Poggioli G, Laureti S, Campieri M, et al. Infliximab in the treatment of Crohn\u2019s disease. Ther Clin Risk Manag. 2007;3(2):301\u20138. https:\/\/doi.org\/10.2147\/tcrm.2007.3.2.301.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"2106_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;45(7):933\u201340. https:\/\/doi.org\/10.1111\/apt.13970.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2106_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ibd\/izaa313","volume":"27","author":"R Battat","year":"2021","unstructured":"Battat R, Lukin D, Scherl EJ, et al. Immunogenicity of tumor necrosis factor antagonists and effect of dose escalation on anti-drug antibodies and serum drug concentrations in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(9):1443\u201351. https:\/\/doi.org\/10.1093\/ibd\/izaa313.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"2106_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/1751-2980.12560","volume":"18","author":"MP Boyle","year":"2017","unstructured":"Boyle MP, Moss AC, O\u2019Toole AM, et al. C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. J Dig Dis. 2017;18(12):678\u201383. https:\/\/doi.org\/10.1111\/1751-2980.12560.","journal-title":"J Dig Dis"},{"issue":"3","key":"2106_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/apt.14452","volume":"47","author":"E Dreesen","year":"2018","unstructured":"Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn\u2019s disease who lose clinical response. Aliment Pharmacol Ther. 2018;47(3):346\u201355. https:\/\/doi.org\/10.1111\/apt.14452.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2106_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/apt.18354","volume":"61","author":"SN Hong","year":"2024","unstructured":"Hong SN, Song JH, Kim SJ, et al. Subcutaneous infliximab concentration thresholds for mucosal and transmural healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2024;61(2):313\u201322. https:\/\/doi.org\/10.1111\/apt.18354.","journal-title":"Aliment Pharmacol Ther"},{"key":"2106_CR7","doi-asserted-by":"publisher","first-page":"175628481875993","DOI":"10.1177\/1756284818759930","volume":"11","author":"A Carlsen","year":"2018","unstructured":"Carlsen A, Omdal R, Leitao K\u00d8, et al. Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn\u2019s disease. Therap Adv Gastroenterol. 2018;11:1756284818759930. https:\/\/doi.org\/10.1177\/1756284818759930.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"2106_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/meg.0000000000000544","volume":"28","author":"A Bond","year":"2016","unstructured":"Bond A, Asher R, Jackson R, et al. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. Eur J Gastroenterol Hepatol. 2016;28(3):271\u20136. https:\/\/doi.org\/10.1097\/meg.0000000000000544.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2106_CR9","doi-asserted-by":"publisher","first-page":"720694","DOI":"10.3389\/fphar.2021.720694","volume":"12","author":"J Peng","year":"2021","unstructured":"Peng J, Jury EC, D\u00f6nnes P, et al. Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges. Front Pharmacol. 2021;12:720694. https:\/\/doi.org\/10.3389\/fphar.2021.720694.","journal-title":"Front Pharmacol"},{"key":"2106_CR10","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"issue":"1","key":"2106_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3\u201325. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw168.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2106_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1751-2980.12994","volume":"22","author":"A IBDGoCM","year":"2021","unstructured":"IBDGoCM A. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis. 2021;22(6):298\u2013317. https:\/\/doi.org\/10.1111\/1751-2980.12994.","journal-title":"J Dig Dis."},{"issue":"5","key":"2106_CR13","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/med.21893","volume":"42","author":"D Liu","year":"2022","unstructured":"Liu D, Saikam V, Skrada KA, et al. Inflammatory bowel disease biomarkers. Med Res Rev. 2022;42(5):1856\u201387. https:\/\/doi.org\/10.1002\/med.21893.","journal-title":"Med Res Rev"},{"issue":"1","key":"2106_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12967-024-05058-1","volume":"22","author":"M Kumar","year":"2024","unstructured":"Kumar M, Murugesan S, Ibrahim N, et al. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. J Transl Med. 2024;22(1):284. https:\/\/doi.org\/10.1186\/s12967-024-05058-1.","journal-title":"J Transl Med"},{"issue":"7","key":"2106_CR15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320-1329.e3. https:\/\/doi.org\/10.1053\/j.gastro.2015.02.031.","journal-title":"Gastroenterology"},{"issue":"14","key":"2106_CR16","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/cm9.0000000000003222","volume":"137","author":"Inflammatory Bowel Disease Group CSoGCMA","year":"2024","unstructured":"Inflammatory Bowel Disease Group CSoGCMA, China IBDQCCo. Chinese clinical practice guideline on the management of Crohn\u2019s disease (2023, Guangzhou). Chin Med J (Engl). 2024;137(14):1647\u201350. https:\/\/doi.org\/10.1097\/cm9.0000000000003222.","journal-title":"Chin Med J (Engl)"},{"issue":"04","key":"2106_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3760\/cma.j.issn.2096-367X.2018.04.003","volume":"02","author":"Association IBDGCSoGCM","year":"2018","unstructured":"Association IBDGCSoGCM. Chinese experts consensus on therapeutic drug monitoring of inflammatory bowel disease. Chin J Inflamm Bowel Dis. 2018;02(04):253\u20139. https:\/\/doi.org\/10.3760\/cma.j.issn.2096-367X.2018.04.003.","journal-title":"Chin J Inflamm Bowel Dis."},{"issue":"1","key":"2106_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12911-024-02752-4","volume":"24","author":"Z Wei","year":"2024","unstructured":"Wei Z, Li M, Zhang C, et al. Machine learning-based predictive model for post-stroke dementia. BMC Med Inform Decis Mak. 2024;24(1):334. https:\/\/doi.org\/10.1186\/s12911-024-02752-4.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"2106_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1186\/s12967-025-07154-2","volume":"23","author":"S Li","year":"2025","unstructured":"Li S, Jiang Y, Hu H, et al. Maternal predictors of early-onset sepsis in neonates: a multicenter retrospective cohort study and risk prediction model. J Transl Med. 2025;23(1):1114. https:\/\/doi.org\/10.1186\/s12967-025-07154-2.","journal-title":"J Transl Med"},{"issue":"5","key":"2106_CR20","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s11096-025-01946-8","volume":"47","author":"W Du","year":"2025","unstructured":"Du W, Chen W, Zhang D, et al. Establishment and validation of a predictive nomogram for voriconazole-associated liver injury in lung transplant patients. Int J Clin Pharm. 2025;47(5):1416\u201326. https:\/\/doi.org\/10.1007\/s11096-025-01946-8.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2106_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/joim.13495","volume":"292","author":"MK Brun","year":"2022","unstructured":"Brun MK, Goll GL, J\u00f8rgensen KK, et al. Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med. 2022;292(3):477\u201391. https:\/\/doi.org\/10.1111\/joim.13495.","journal-title":"J Intern Med"},{"issue":"12","key":"2106_CR22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247\u201359. https:\/\/doi.org\/10.1097\/MIB.0000000000000212.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2106_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","volume":"64","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease. Gut. 2015;64(10):1539\u201345. https:\/\/doi.org\/10.1136\/gutjnl-2014-307883.","journal-title":"Gut"},{"issue":"1","key":"2106_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib13010016","volume":"13","author":"T Velikova","year":"2024","unstructured":"Velikova T, Sekulovski M, Peshevska-Sekulovska M. Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development. Antibodies (Basel). 2024;13(1):16\u201331. https:\/\/doi.org\/10.3390\/antib13010016.","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"2106_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40265-024-02115-3","volume":"85","author":"OH Nielsen","year":"2025","unstructured":"Nielsen OH, Hammerh\u00f8j A, Ainsworth MA, et al. Immunogenicity of therapeutic antibodies used for inflammatory bowel disease: treatment and clinical considerations. Drugs. 2025;85(1):67\u201385. https:\/\/doi.org\/10.1007\/s40265-024-02115-3.","journal-title":"Drugs"},{"issue":"4","key":"2106_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm14041057","volume":"14","author":"M Shehab","year":"2025","unstructured":"Shehab M, Alrashed F. Age as a predictor of serum tumor necrosis factor antagonist drug and antidrug antibody concentrations in inflammatory bowel disease-a nationwide cohort study. J Clin Med. 2025;14(4):1\u201314. https:\/\/doi.org\/10.3390\/jcm14041057.","journal-title":"J Clin Med"},{"issue":"12","key":"2106_CR27","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1093\/ibd\/izad305","volume":"30","author":"AS Faye","year":"2024","unstructured":"Faye AS, Lee KE, Hudesman D, et al. Older adults with inflammatory bowel disease are at higher risk of developing antibodies to infliximab. Inflamm Bowel Dis. 2024;30(12):2509\u201311. https:\/\/doi.org\/10.1093\/ibd\/izad305.","journal-title":"Inflamm Bowel Dis"},{"key":"2106_CR28","doi-asserted-by":"publisher","first-page":"115281","DOI":"10.1016\/j.biopha.2023.115281","volume":"166","author":"J Gouju","year":"2023","unstructured":"Gouju J, Legeay S. Pharmacokinetics of obese adults: not only an increase in weight. Biomed Pharmacother. 2023;166:115281. https:\/\/doi.org\/10.1016\/j.biopha.2023.115281.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"2106_CR29","doi-asserted-by":"publisher","first-page":"e00233","DOI":"10.14309\/ctg.0000000000000233","volume":"11","author":"Z Lim","year":"2020","unstructured":"Lim Z, Welman CJ, Raymond W, et al. The effect of adiposity on anti-tumor necrosis factor-alpha levels and loss of response in Crohn\u2019s disease patients. Clin Transl Gastroenterol. 2020;11(9):e00233. https:\/\/doi.org\/10.14309\/ctg.0000000000000233.","journal-title":"Clin Transl Gastroenterol"},{"key":"2106_CR30","doi-asserted-by":"publisher","first-page":"175628482311719","DOI":"10.1177\/17562848231171962","volume":"16","author":"K Li","year":"2023","unstructured":"Li K, Gong P, Zhang Y, et al. Effects of visceral adipose tissue on anti-tumour necrosis factor-\u03b1 in Crohn\u2019s disease. Therap Adv Gastroenterol. 2023;16:17562848231171962. https:\/\/doi.org\/10.1177\/17562848231171962.","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"2106_CR31","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","volume":"8","author":"C Passot","year":"2016","unstructured":"Passot C, Mulleman D, Bejan-Angoulvant T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs. 2016;8(7):1407\u201316.","journal-title":"MAbs"},{"issue":"1","key":"2106_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12969-021-00548-8","volume":"19","author":"RS Funk","year":"2021","unstructured":"Funk RS, Shakhnovich V, Cho YK, et al. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Pediatr Rheumatol Online J. 2021;19(1):62\u201373. https:\/\/doi.org\/10.1186\/s12969-021-00548-8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"2106_CR33","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/pharmaceutics13111821","volume":"13","author":"D Ternant","year":"2021","unstructured":"Ternant D, Le Tilly O, Picon L, et al. Infliximab efficacy may be linked to full TNF-\u03b1 blockade in peripheral compartment-a double central-peripheral target-mediated drug disposition (TMDD) model. Pharmaceutics. 2021;13(11):1821\u201334. https:\/\/doi.org\/10.3390\/pharmaceutics13111821.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2106_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/ibd\/izz195","volume":"26","author":"B Barberio","year":"2020","unstructured":"Barberio B, D\u2019Inc\u00e0 R, Facchin S, et al. Matrix metalloproteinase 3 predicts therapeutic response in inflammatory bowel disease patients treated with infliximab. Inflamm Bowel Dis. 2020;26(5):756\u201363. https:\/\/doi.org\/10.1093\/ibd\/izz195.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2106_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.016.","journal-title":"Gastroenterology"},{"issue":"3","key":"2106_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.18773\/austprescr.2015.034","volume":"38","author":"M Harrison","year":"2015","unstructured":"Harrison M. Erythrocyte sedimentation rate and C-reactive protein. Aust Prescr. 2015;38(3):93\u20134. https:\/\/doi.org\/10.18773\/austprescr.2015.034.","journal-title":"Aust Prescr"},{"issue":"4","key":"2106_CR37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/jgh.16895","volume":"40","author":"K Cameron","year":"2025","unstructured":"Cameron K, Nguyen AL, Gibson DJ, et al. Review article: Albumin and its role in inflammatory bowel disease: the old, the new, and the future. J Gastroenterol Hepatol. 2025;40(4):808\u201320. https:\/\/doi.org\/10.1111\/jgh.16895.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"2106_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211\u201328. https:\/\/doi.org\/10.1007\/s00228-009-0718-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"2106_CR39","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.cgh.2023.03.044","volume":"21","author":"V Solitano","year":"2023","unstructured":"Solitano V, Facciorusso A, McGovern DPB, et al. HLA-DQA1\u221705 genotype and immunogenicity to tumor necrosis factor-\u03b1 antagonists: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(12):3019\u201329. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.044.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2106_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/flgastro-2014-100441","volume":"5","author":"J Turvill","year":"2014","unstructured":"Turvill J. Mapping of Crohn\u2019s disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol. 2014;5(3):167\u201375. https:\/\/doi.org\/10.1136\/flgastro-2014-100441.","journal-title":"Frontline Gastroenterol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02106-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02106-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02106-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:04Z","timestamp":1784035864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02106-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02106-2","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no declared conflicts of interest among the authors with respect to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Compliance with the Declaration of Helsinki was ensured throughout the study, which was subsequently reviewed and granted approval by the Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University (No. 2024ZSLYEC-405). Informed consent was waived by the committee for this retrospective study as it involved no more than minimal risk and all data were analyzed anonymously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}